CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 1.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 77,702 shares of the company’s stock after buying an additional 1,133 shares during the period. Bank of New York Mellon Corp owned approximately 0.09% of CRISPR Therapeutics worth $2,644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Teacher Retirement System of Texas lifted its stake in shares of CRISPR Therapeutics by 18.5% in the 4th quarter. Teacher Retirement System of Texas now owns 23,969 shares of the company’s stock valued at $943,000 after purchasing an additional 3,736 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at about $634,000. LPL Financial LLC lifted its position in CRISPR Therapeutics by 39.3% in the fourth quarter. LPL Financial LLC now owns 149,726 shares of the company’s stock valued at $5,893,000 after buying an additional 42,232 shares during the last quarter. Vanguard Group Inc. boosted its stake in CRISPR Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company’s stock worth $68,329,000 after buying an additional 10,579 shares during the period. Finally, Congress Wealth Management LLC DE acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at about $222,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. The Goldman Sachs Group decreased their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a report on Thursday, May 8th. JMP Securities reissued a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Barclays dropped their price objective on CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a research note on Friday, May 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $81.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, July 8th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $71.31.

Insiders Place Their Bets

In related news, insider Naimish Patel sold 3,932 shares of the stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider owned 6,068 shares of the company’s stock, valued at $218,083.92. This represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Simeon George purchased 989,812 shares of the firm’s stock in a transaction on Wednesday, July 16th. The shares were acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the acquisition, the director directly owned 1,730,179 shares in the company, valued at $90,021,213.37. The trade was a 133.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $64.76 on Monday. The business has a 50-day simple moving average of $47.56 and a 200-day simple moving average of $42.74. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $71.13. The company has a market cap of $5.59 billion, a PE ratio of -14.33 and a beta of 1.82.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same quarter last year, the firm posted ($1.43) EPS. The company’s revenue was up 71.6% compared to the same quarter last year. On average, sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.